ACE and COVID-19: In an observational study including 1686 patients hospitalized for COVID-19, use of ACE inhibitors or angiotensin receptor blockers (ARBs) was associated with lower levels of inflammation and lower risk of the composite outcome of in-hospital death, mechanical ventilation, or dialysis [23].